Citation Tools
Clinical/translational cancer immunotherapy
Original research
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma